Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: The Phase III SPR1NT trial

Authors

Kevin A Strauss, University of Massachusetts
Craig M Zaidman, Washington University School of Medicine in St. Louis
et al

Journal

Nature Medicine

Publication Date

7-1-2022

Volume

28

Issue

7

First Page

1390

Last Page

1397

Document Type

Open Access Publication

DOI

10.1038/s41591-022-01867-3

Rights and Permissions

Strauss, K.A., Farrar, M.A., Muntoni, F. et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med 28, 1390–1397 (2022). https://doi.org/10.1038/s41591-022-01867-3 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Recommended Citation

Strauss, Kevin A; Zaidman, Craig M; and et al, "Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: The Phase III SPR1NT trial." Nature Medicine. 28, 7. 1390 - 1397. (2022).
https://digitalcommons.wustl.edu/oa_4/25